FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

STATEMENT	OF CHANGES	IN BENEFICIAL	OWNERSHIP

OMB APPROVAL										
OMB Number:	3235-0287									
Estimated average b	ourden									
hours per response:	0.5									

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b)

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

					۱		Manage			alta.	0		-	Dalatianal :	. (D		(-) +- :	
1. Name and Address of Reporting Person*				2. Issuer Name and Ticker or Trading Symbol Cullinan Oncology, Inc. CGEM								5. Relationship of Reporting Person(s) to Issuer (Check all applicable)						
Baeuer	le Patric	<u>k</u>				шш	an On	CO10	<u>gy, in</u>	<u>. </u>	CGEM]		1,0	Directo			10% O	wner
					.									Officer	(give title		Other (· .
					2 [2. Data of Farlingt Transaction (Month/Day/Year)								below) below)				
(Last)	`	•	(Middle)			3. Date of Earliest Transaction (Month/Day/Year) 02/11/2022								See Remarks				
C/O CUI	LLINAN (ONCOLOGY, INC	Ξ.		102	02/11/2022								See Remarks				
ONE MA	AIN STRE	ET SHITE 520																
ONE MAIN STREET, SUITE 520				4 1	4. If Amendment, Date of Original Filed (Month/Day/Year)								6. Individual or Joint/Group Filing (Check Applicable					
(041)					-	17 11110	marmorn, i	Date (or Origino		a (monanze	ty/ rour)	Lii		01100	.pو	y (Oncon 7 h	phicable
(Street)														X Form f	iled by Or	ne Repo	orting Perso	on
CAMBR	IDGE N	MΑ	02142											Form f	iled by Mo	re than	n One Repo	orting
-					-									Persor		ne tria	Tone Repo	, and
(City)	(State)	(Zip)															- 1
		Tab	le I - No	n-Deriv	vativ	e Se	curities	s Ac	quired	, Dis	sposed o	f, or Be	neficia	lly Owned				
1. Title of S	Security (In:	str. 3)		2. Transa	action	Execution Date,			3.		4. Securiti	es Acquirec	l (A) or	or 5. Amount of		6. Ownership		7. Nature of
	, ,	,		Date					Transaction Disposed Of		Of (D) (Instr	. 3, 4 and		Securities			Indirect Beneficial	
(Month/Da			ay/ Yea	y/Year) if any (Month/Day/Year)				Code (Instr. 5)				Beneficially Owned Followir		(D) or Indirect (I) (Instr. 4)		Ownership		
				l		` '			H		_	(A) or		Reported Transacti	- on(o)	' '	[·	(Instr. 4)
									Code	v	Amount	(A) or (D)	Price	(Instr. 3 a				
Common Stock 02/11/2				/2022	0022			A		37,500 ⁽	1) A	\$0.0	0 37,500		D			
Common Stock 02/11/2			/2022						37,300	, A	Ψ0.0	J 37,	J00		D			
												241	42.4		, l:	See		
Common Stock												341,	434		I	footnote ⁽²⁾		
	Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned																	
			Table II -											y Owned				
				(e.g., p	outs,	can	s, warr	ants	, optio	ns,	convertil	oie secu	rities)					
					4.					6. Date Exercisable and 7. Title and An				9. Number of		10.	11. Nature	
Derivative Conversion Date Execution Date Security or Exercise (Month/Day/Year) if any						ction Instr			Expiration Dat (Month/Day/Ye			of Securities Underlying		Derivative Security	derivative Securities		Ownership Form:	ip of Indirect Beneficial
(Instr. 3) Price of (Month/Day/Year) 8) Securities				Derivative Secu			(Instr. 5)	Benefici	neficially Dire		(D) Ownership
	Derivative Security						Acquire (A) or	ed				(Instr. 3 ar	nd 4)	1	Owned Followin			
	Occurry					Disposed		Disposed						1	Reported	eported `		′ I
						of (D) (Instr. 3, 4 and 5)								Transact (Instr. 4)	Transaction(s)			
		H			3, 4 and 3,							-	(1113411.4)	'				
													Amount or					1
									D-4-		Frankatia		Number					
				- 1	Code	v	(A)	(D)	Date Exercisa	ıble	Expiration Date	Title	of Shares					
Stock														Ť T				
Option	\$13.6	02/11/2022			Α		75,000		(3)		02/10/2032	Common	75,000	\$0.00	75,0	00	D	
(Right to Buy)												Stock	5,500		"			

Explanation of Responses:

- 1. The shares underlying the restricted stock unit vest over four years, with one forty-eighty (1/48th) of the shares vesting in equal monthly installments until the fourth anniversary of the grant date.
- 2. Shares held directly by APAK Solutions GmbH. The Reporting Person is managing director of APAK Solutions GmbH. The Reporting Person disclaims beneficial ownership of the securities reported herein except to the extent of his pecuniary interest therein.
- 3. The shares underlying the option vest over four years, with one forty-eighty (1/48th) of the shares vesting in equal monthly installments until the fourth anniversary of the grant date.

Remarks:

Acting Chief Scientific Officer, Biologics

/s/ Jeffrey Trigilio, Attorney-in-

02/15/2022

Fact

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.